This trial will study the safety and efficacy of cultured allogeneic adult umbilical cord derived mesenchymal stem cells delivered intravenously for the treatment of Polycystic Ovary Syndrome.
Stem cell treatment has shown efficacy for PCOS in both human and animal studies. Complete resolution was seen of polycystic ovary syndrome (PCOS) in a young woman after a single intravenous injection of umbilical cord derived mesenchymal stem cells (UCDSC). It is hypothesized that intravenous infusion of UCDSC can reduce or eliminate PCOS. Patients will receive roughly 2 million umbilical cord derived mesenchymal stem cells per kg of body weight. Hormone levels and ultrasound will be checked 3,6 and 12 months after treatment.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
20
Cultured allogeneic adult umbilical cord derived mesenchymal stem cells
Medical Surgical Associates Center
St John's, Antigua and Barbuda
RECRUITINGAthens Beverly Hills Medical Group
Glyfada, Greece
RECRUITINGSafety: Adverse Events
Clinical monitoring of possible adverse events or complications
Time frame: Four year follow-up
Efficacy: Global Improvement Score (GI)
Ranging from 0 to 100%
Time frame: Four year follow-up
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.